medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2022, Number 2

<< Back Next >>

Arch Neurocien 2022; 27 (2)

Therapeutic potential of dehydroepiandrosterone for Parkinson’s disease: scoping review protocol

Pérez-Neri I, Diéguez-Campa CE, Sandoval H, Chávez Vivian-Aleisha, Castro-Martínez E, Ríos C

Language: English
References: 41
Page: 39-46
PDF size: 200.71 Kb.


ABSTRACT

Background: Parkinson’s disease (PD) is a neurodegenerative disorder characterized by a progressive loss of nigrostriatal dopaminergic neurons. Its treatment is symptomatic and shows limited efficacy. Dehydroepiandrosterone (DHEA) is a hormone produced in the brain. Several studies have reported beneficial effects of said steroid in experimental models of PD and various human diseases, but its potential for PD is inconclusive. Therefore, it is necessary to evaluate current evidence to determine the therapeutic potential of DHEA administration for PD since it could be an effective and low-cost treatment.
Objectives: This scoping review protocol aims to evaluate the therapeutic potential of dehydroepiandrosterone administration in patients with PD. Inclusion criteria: Studies describing patients with PD receiving DHEA, and reporting an outcome --on disease course, severity, or adverse effects-- compared to either placebo, an inactive treatment or a standard treatment will be included. Also, PD experimental models reporting an effect of DHEA treatment on measures of neuroprotection (cell death, motor activity, oxidative stress) will be considered. Exclusion criteria: Studies written in languages different than Spanish or English that could not be appropriately translated, or whose fulltext files could not be retrieved will be discarded. Information sources: Studies will be retrieved from Web of Science, PubMed, Scopus, EBSCOhost, Cochrane Library, Google Scholar, and author’s collections. No other sources will be considered. Data charting: Data will be extracted by one researcher and verified by another using a pilot-tested predefined format. Non-systematic review articles (narrative, scoping or similar) will only be considered for narrative synthesis. This protocol complies with the PRISMA 2020 statement and its main related extensions (PRISMA-A, PRISMA-P, PRISMA-Scr). It also complies with the Manual for Evidence Synthesis of the Joanna Briggs Institute.


REFERENCES

  1. Baltasar-Rodríguez LM, Millán-Guerrero RO, Aceves-ThemselR, Isais-Millán S, Delgado-Enciso I. Longitudinal study ofthree families with familial Parkinson’s disease. Gac Med Mex. 2006;142(5):387-91.

  2. Choe MA, An GJ, Koo BS, Jeon S. Effect of DHEA on recovery ofmuscle atrophy induced by Parkinson’s disease. J Korean AcadNurs. 2011;41(6):834-42.

  3. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J.Epidemiology and etiology of Parkinson’s disease: a review ofthe evidence. Eur J Epidemiol. 2011;26 Suppl 1:S1-58.

  4. Rizek P, Kumar N, Jog MS. An update on the diagnosis andtreatment of Parkinson disease. CMAJ. 2016;188(16):1157-65.

  5. Yilmaz C, Karali K, Fodelianaki G, Gravanis A, Chavakis T,Charalampopoulos I, et al. Neurosteroids as regulators ofneuroinflammation. Front Neuroendocrinol. 2019;55:100788.

  6. Carlström K, Brody S, Lunell NO, Lagrelius A, MöllerströmG, Pousette A, et al. Dehydroepiandrosterone sulphate anddehydroepiandrosterone in serum: differences related to ageand sex. Maturitas. 1988;10(4):297-306.

  7. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changesand sex differences in serum dehydroepiandrosterone sulfateconcentrations throughout adulthood. J Clin Endocrinol Metab.1984;59(3):551-5.

  8. Van Vollenhoven RF, McGuire JL. Studies of dehydroepiandrosterone(DHEA) as a therapeutic agent in systemic lupus erythematosus.Ann Med Interne (Paris). 1996;147(4):290-6.

  9. Pérez-Neri I, Ríos C. The role of DHEA in mental disorders. In:Watson R, editor. DHEA in Human Health and Aging. BocaRaton: CRC Press; 2011. p. 239-52.

  10. Andus T, Klebl F, Rogler G, Bregenzer N, Schölmerich J, StraubRH. Patients with refractory Crohn’s disease or ulcerative colitisrespond to dehydroepiandrosterone: a pilot study. AlimentPharmacol Ther. 2003;17(3):409-14.

  11. Fouany MR, Sharara FI. Is there a role for DHEA supplementationin women with diminished ovarian reserve. J Assist Reprod Genet.2013;30(9):1239-44.

  12. Nagels HE, Rishworth JR, Siristatidis CS, Kroon B. Androgens(dehydroepiandrosterone or testosterone) for womenundergoing assisted reproduction. Cochrane Database Syst Rev.2015;(11):CD009749.

  13. Evans TG, Judd ME, Dowell T, Poe S, Daynes RA, Araneo BA.The use of oral dehydroepiandrosterone sulfate as an adjuvantin tetanus and influenza vaccination of the elderly. Vaccine.1996;14(16):1531-37.

  14. Debonneuil EH, Quillard J, Baulieu EE. Hypoxia anddehydroepiandrosterone in old age: a mouse survival study.Respir Res. 2006;7:144.

  15. Dluzen DE, McDermott JL, Liu B. Estrogen as a neuroprotectantagainst MPTP-induced neurotoxicity in C57/B1 mice.Neurotoxicol Teratol. 1996;18(5):603-6.

  16. Miller DB, Ali SF, O’Callaghan JP, Laws SC. The Impact of Genderand Estrogen on Striatal Dopaminergic Neurotoxicity. Ann N YAcad Sci. 1998;844(1):153-65.

  17. Murray HE, Pillai AV, McArthur SR, Razvi N, Datla KP, DexterDT, et al. Dose- and sex-dependent effects of the neurotoxin6-hydroxydopamine on the nigrostriatal dopaminergic pathwayof adult rats: differential actions of estrogen in males andfemales. Neuroscience. 2003;116(1):213-22.

  18. D’Astous M, Morissette M, Tanguay B, Callier S, Di Paolo T.Dehydroepiandrosterone (DHEA) such as 17beta-estradiolprevents MPTP-induced dopamine depletion in mice. Synapse.2003;47(1):10-14.

  19. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, PetticrewM, et al. Preferred reporting items for systematic review andmeta-analysis protocols (PRISMA-P) 2015: elaboration andexplanation. BMJ. 2015;350:g7647.

  20. Esam H, Kanukula R, Dhurjati R, Aerram R, Chevireddy S,Bhaumik S, et al. Systematic reviews of antihypertensive drugs:A review of publication trends, characteristics, and quality. J ClinHypertens (Greenwich). 2021;23(5):915-22.

  21. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,et al. Cochrane handbook for systematic reviews of interventions.Chichester: John Wiley & Sons; 2019.

  22. Rosca EC, Tudor R, Cornea A, Simu M. Parkinson’s Disease inRomania: A Scoping Review Protocol. Brain Sci. 2021;11(2):251.

  23. Polhemus AM, Bergquist R, Bosch de Basea M, Brittain G,Buttery SC, Chynkiamis N, et al. Walking-related digital mobilityoutcomes as clinical trial endpoint measures: protocol for ascoping review. BMJ Open. 2020;10(7):e038704.

  24. Aromataris E, Munn Z, editors. JBI Manual for Evidence Synthesis.Adelaide: Joanna Briggs Institute; 2020.

  25. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, MulrowCD, et al. PRISMA 2020 explanation and elaboration: updatedguidance and exemplars for reporting systematic reviews. BMJ.2021;372:n160.

  26. Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H,Chalmers I, et al. PRISMA for Abstracts: reporting systematicreviews in journal and conference abstracts. PLoS Med.2013;10(4):e1001419.

  27. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, etal. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklistand Explanation. Ann Intern Med. 2018;169(7):467-73.

  28. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V,Lefebvre C. PRESS Peer Review of Electronic Search Strategies:2015 Guideline Statement. J Clin Epidemiol. 2016;75:40-6.

  29. Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D,Page MJ, et al. PRISMA-S: an extension to the PRISMA Statementfor Reporting Literature Searches in Systematic Reviews. Syst Rev.2021;10(1):39.

  30. Willcox MDP, Walsh K, Nichols JJ, Morgan PB, Jones LW. Theocular surface, coronaviruses and COVID -19. Clin Exp Optom.2020;103(4):418-24.

  31. Pérez-Neri I, González-Aguilar A, Sandoval H, Pineda C,Ríos C. Therapeutic Potential of Ultrasound Neuromodulationin Decreasing Neuropathic Pain: Clinical and ExperimentalEvidence. Curr Neuropharmacol. 2021;19(3):334-48.

  32. McKeown S, Mir ZM. Considerations for conducting systematic reviews: evaluating the performance of different methods for de-duplicatingreferences. Syst Rev. 2021;10(1):38.

  33. Bozada T, Borden J, Workman J, Del Cid M, Malinowski J, Luechtefeld T. Sysrev: A FAIR Platform for Data Curation and SystematicEvidence Review. Front Artif Intell. 2021;4:685298.

  34. Khamsi R. Coronavirus in context: Scite.ai tracks positive and negative citations for COVID-19 literature. Nature. 2020.

  35. Haddaway NR, McGuinness LA. PRISMA 2020: R package and ShinyApp for producing PRISMA 2020 compliant flow diagrams (Version0.0.2). medRxiv. 2021:21260492.

  36. O’Neill J, Tabish H, Welch V, Petticrew M, Pottie K, Clarke M, et al. Applying an equity lens to interventions: using PROGRESS ensuresconsideration of socially stratifying factors to illuminate inequities in health. J Clin Epidemiol. 2014;67(1):56-64.

  37. Usher R, Stapleton T. Approaches for assessing decision-making capacity in older adults: a scoping review protocol. JBI Evidence Synthesis.2020;18(4):832-40.

  38. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studiesreporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015;13(3):147-53.

  39. Petticrew M, Roberts H. Systematic Reviews in the Social Sciences: A Practical Guide. Oxford: Wiley-Blackwell; 2006.

  40. Strech D, Synofzik M, Marckmann G. Systematic reviews of empirical bioethics. J Med Ethics. 2008;34(6):472-77.

  41. Tanila T, Tenhunen H, Hirvonen P. Value Mechanisms in the Implementation of Intelligent Patient Flow Management System - A MultipleCase Study. Stud Health Technol Inform. 2020;270:708-12.




2020     |     www.medigraphic.com